Pasteur Institute Launches a Vaccinology Mooc

France
Others
30 July 2015

For the first time Pasteur Institute launches a vaccinology MOOC, available from September 17th, 2015. This course is organized in 6 modules (downloadable videos) over a time period of 6 weeks. There will be weekly tests, a forum, discussions on line through hangouts and a final QCM test. Mind you the MOOC will not replace the standard face-to-face vaccinology course.

syringe-vaccine-bottle.jpg

The objective of this course is to offer an integrated overview of vaccinology, from public health and scientific data justifying the development of a vaccine, to its delivery to the populations in the context of industrialized and developing countries. Dedicated to candidates with a medical or scientific background who are interested in all aspects of vaccinology: medical and public health students, scientific Master II and PhD students (Immunology, Microbiology), physicians, pharmacists, veterinarians and other health professionals. The MOOC is composed of 31 lectures presenting historical aspects of vaccines, immunology and design of vaccines, basic principles of preclinical and clinical development, an update of vaccine development for the major infectious diseases, and the future challenges of vaccinology.

This Mooc is dedicated to doctors, pharmacists, researchers, students, nurses or other staff of public or private hospitals, staff of the pharmaceutical industry or of public health services.

Register now

Related News & Events

  • France
    Agenda & Minutes

    ADVAC Course - Apply Before 15th November

    15.10.2015

    The next ADVAC course will take place in Veyrier du Lac (Annecy), France from 23 May to 3 June 2016 . Please note that the deadline for receipt of applications is 15 November 2015.

    Read more
  • Europe
    Others

    EMA to further clarify safety profile of human papillomavirus (HPV) vaccines

    15.07.2015

    The European Medicines Agency (EMA) has started a review of HPV vaccines to further clarify aspects of their safety profile. These vaccines have been used in around 72 million people worldwide and their use is expected to prevent many cases of cervical cancer (cancer of the neck of the womb) and various other cancers and conditions caused by HPV. Cervical cancer is the 4th most common cause of cancer death in women worldwide, with tens of thousands of deaths in Europe each year despite the existence of screening programmes to identify the cancer early. The review does not question that the benefits of HPV vaccines outweigh their risks.

    Read more
  • Health policy

    Have you ever considered mandatory immunization?

    07.09.2018

    This article analyses countries that implemented mandatory infant and childhood immunization, sharing the best practices and lessons learnt.

    Read more